US Bancorp DE Has $3.61 Million Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

US Bancorp DE boosted its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 552.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 228,301 shares of the company’s stock after purchasing an additional 193,288 shares during the quarter. US Bancorp DE’s holdings in Dr. Reddy’s Laboratories were worth $3,605,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 43.2% in the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock valued at $36,000 after buying an additional 137 shares during the period. POM Investment Strategies LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 400.0% in the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock valued at $36,000 after buying an additional 1,820 shares during the period. Allworth Financial LP boosted its holdings in shares of Dr. Reddy’s Laboratories by 447.8% in the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock valued at $41,000 after buying an additional 2,230 shares during the period. Sierra Ocean LLC acquired a new position in shares of Dr. Reddy’s Laboratories in the fourth quarter valued at approximately $43,000. Finally, Independence Bank of Kentucky boosted its holdings in shares of Dr. Reddy’s Laboratories by 400.0% in the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company’s stock valued at $44,000 after buying an additional 2,220 shares during the period. Institutional investors and hedge funds own 3.85% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on RDY shares. Barclays reduced their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. Finally, StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY opened at $12.92 on Thursday. Dr. Reddy’s Laboratories Limited has a 12 month low of $12.62 and a 12 month high of $16.89. The firm has a fifty day simple moving average of $14.34 and a 200 day simple moving average of $15.00. The stock has a market capitalization of $10.78 billion, a price-to-earnings ratio of 20.57 and a beta of 0.50. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Research analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.